Drug intelligence / Profile preview

adecatumumab-IRDye800CW

Development stage: Unknown
Lead developer: Amgen
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

IRDye800CW-MT201 is a near-infrared (NIR) fluorescently labeled monoclonal antibody developed for fluorescence-guided surgery (FGS). It consists of the human IgG1 monoclonal antibody adecatumumab (MT201), which targets the epithelial cell adhesion molecule (EpCAM), conjugated to the NIR fluorophore IRDye 800CW. EpCAM is a transmembrane glycoprotein that is highly overexpressed in various epithelial malignancies, including head and neck squamous cell carcinoma (HNSCC), while showing limited expression in normal tissues. By binding to EpCAM-positive tumor cells, IRDye800CW-MT201 enables real-time intraoperative visualization of primary tumors, surgical margins, and occult metastases using NIR imaging systems. This targeted imaging approach aims to assist surgeons in achieving complete tumor resection and improving oncological outcomes.

Other names: IRDye800CW-adecatumumabIRDye-800CW-adecatumumabIRDye 800CW-adecatumumab

Targets

EPCAM (Epithelial cell adhesion molecule)

Beyond the preview

Go deeper on adecatumumab-IRDye800CW.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on adecatumumab-IRDye800CW.

Explore the full profile